ID   L1CAM_HUMAN             Reviewed;        1257 AA.
AC   P32004; A0AV65; A4ZYW4; B2RMU7; G3XAF4; Q8TA87;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   28-JUN-2023, entry version 236.
DE   RecName: Full=Neural cell adhesion molecule L1;
DE            Short=N-CAM-L1;
DE            Short=NCAM-L1;
DE   AltName: CD_antigen=CD171;
DE   Flags: Precursor;
GN   Name=L1CAM; Synonyms=CAML1, MIC5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=1932117; DOI=10.1016/0167-4781(91)90108-x;
RA   Kobayashi M., Miura M., Asou H., Uyemura K.;
RT   "Molecular cloning of cell adhesion molecule L1 from human nervous tissue:
RT   a comparison of the primary sequences of L1 molecules of different
RT   origin.";
RL   Biochim. Biophys. Acta 1090:238-240(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=1769655; DOI=10.1016/0888-7543(91)90150-d;
RA   Hlavin M.L., Lemmon V.;
RT   "Molecular structure and functional testing of human L1CAM: an interspecies
RT   comparison.";
RL   Genomics 11:416-423(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=1627459; DOI=10.1007/bf02919404;
RA   Reid R.A., Hemperly J.J.;
RT   "Variants of human L1 cell adhesion molecule arise through alternate
RT   splicing of RNA.";
RL   J. Mol. Neurosci. 3:127-135(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9286695; DOI=10.1006/geno.1997.4822;
RA   Brenner V., Nyakatura G., Rosenthal A., Platzer M.;
RT   "Genomic organization of two novel genes on human Xq28: compact head to
RT   head arrangement of IDH gamma and TRAP delta is conserved in rat and
RT   mouse.";
RL   Genomics 44:8-14(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=9479034; DOI=10.1016/s0378-1119(97)00614-8;
RA   Coutelle O., Nyakatura G., Taudien S., Elgar G., Brenner S., Platzer M.,
RA   Drescher B., Jouet M., Kenwrick S., Rosenthal A.;
RT   "The neural cell adhesion molecule L1: genomic organisation and
RT   differential splicing is conserved between man and the pufferfish Fugu.";
RL   Gene 208:7-15(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Son Y.S.;
RL   Submitted (MAR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 20-36.
RX   PubMed=3136168; DOI=10.1016/s0021-9258(18)37877-3;
RA   Wolff J.M., Frank R., Mujoo K., Spiro R.C., Reisfeld R.A., Rathjen F.G.;
RT   "A human brain glycoprotein related to the mouse cell adhesion molecule
RT   L1.";
RL   J. Biol. Chem. 263:11943-11947(1988).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 332-371.
RX   PubMed=2387585; DOI=10.1016/0888-7543(90)90203-7;
RA   Djabali M., Mattei M.-G., Nguyen C., Roux D., Demengeot J., Denizot F.,
RA   Moos M., Schachner M., Goridis C., Jordan B.R.;
RT   "The gene encoding L1, a neural adhesion molecule of the immunoglobulin
RT   family, is located on the X chromosome in mouse and man.";
RL   Genomics 7:587-593(1990).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 353-1176, AND NUCLEOTIDE SEQUENCE [GENOMIC
RP   DNA] OF 1082-1176.
RC   TISSUE=Fetal brain;
RX   PubMed=1923824; DOI=10.1093/nar/19.19.5395;
RA   Rosenthal A., Mackinnon R.N., Jones D.S.C.;
RT   "PCR walking from microdissection clone M54 identifies three exons from the
RT   human gene for the neural cell adhesion molecule L1 (CAM-L1).";
RL   Nucleic Acids Res. 19:5395-5401(1991).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1030-1257.
RX   PubMed=1993895; DOI=10.1111/j.1471-4159.1991.tb01994.x;
RA   Harper J.R., Prince J.T., Healy P.A., Stuart J.K., Nauman S.J.,
RA   Stallcup W.B.;
RT   "Isolation and sequence of partial cDNA clones of human L1: homology of
RT   human and rodent L1 in the cytoplasmic region.";
RL   J. Neurochem. 56:797-804(1991).
RN   [14]
RP   PHOSPHORYLATION AT SER-1181.
RX   PubMed=8592152; DOI=10.1046/j.1471-4159.1996.66020779.x;
RA   Wong E.V., Schaefer A.W., Landreth G., Lemmon V.;
RT   "Casein kinase II phosphorylates the neural cell adhesion molecule L1.";
RL   J. Neurochem. 66:779-786(1996).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-671.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1163, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1248, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-671.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   INVOLVEMENT IN L1 SYNDROME, VARIANTS 26-TYR--GLU-1257 DEL; ASN-37; MET-38;
RP   66-GLN--GLU-1257 DEL; 109-GLN--GLU-1257 DEL; 133-GLU--GLU-1257 DEL;
RP   138-TRP--GLU-1257 DEL; ILE-172; GLY-184; 187-MET--VAL-198 DEL; ASP-254;
RP   ARG-276; PRO-313; 366-TRP--GLU-1257 DEL; LYS-369; 423-GLN--GLU-1257 DEL;
RP   ARG-480; ASN-516; TYR-516; HIS-525; MET-627; PRO-645; 662-TRP--GLU-1257
RP   DEL; SER-714; ARG-754; 760-ARG--GLU-1257 DEL; 789-GLN--GLU-1257 DEL;
RP   811-TYR--GLU-1257 DEL; 891-TYR--GLU-1257 DEL; 901-ARG--GLU-1257 DEL;
RP   1064-SER--GLU-1257 DEL; ASN-1071 DEL AND GLN-1080, VARIANTS MASA SER-179;
RP   TYR-202; ARG-335 AND MET-752, AND VARIANTS HYCX SER-179; GLN-184; ARG-335;
RP   PRO-415 AND MET-752.
RX   PubMed=19846429; DOI=10.1136/jmg.2009.071688;
RA   Vos Y.J., de Walle H.E., Bos K.K., Stegeman J.A., Ten Berge A.M.,
RA   Bruining M., van Maarle M.C., Elting M.W., den Hollander N.S., Hamel B.,
RA   Fortuna A.M., Sunde L.E., Stolte-Dijkstra I., Schrander-Stumpel C.T.,
RA   Hofstra R.M.;
RT   "Genotype-phenotype correlations in L1 syndrome: a guide for genetic
RT   counselling and mutation analysis.";
RL   J. Med. Genet. 47:169-175(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1194, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-1177 (ISOFORM 2), PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-1172 (ISOFORM 3), AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1177 (ISOFORM 2),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1172 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [23]
RP   INVOLVEMENT IN L1 SYNDROME, VARIANTS CYS-635 AND ILE-768, AND
RP   GLYCOSYLATION.
RX   PubMed=22222883; DOI=10.1007/s10048-011-0307-4;
RA   Marx M., Diestel S., Bozon M., Keglowich L., Drouot N., Bouche E.,
RA   Frebourg T., Minz M., Saugier-Veber P., Castellani V., Schaefer M.K.;
RT   "Pathomechanistic characterization of two exonic L1CAM variants located in
RT   trans in an obligate carrier of X-linked hydrocephalus.";
RL   Neurogenetics 13:49-59(2012).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1243, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   VARIANT HYCX TYR-264.
RX   PubMed=8401576; DOI=10.1038/ng0893-331;
RA   Jouet M., Rosenthal A., Macfarlane J., Kenwrick S., Donnai D.;
RT   "A missense mutation confirms the L1 defect in X-linked hydrocephalus
RT   (HSAS).";
RL   Nat. Genet. 4:331-331(1993).
RN   [26]
RP   VARIANT HYCX LEU-1194, AND VARIANT MASA LEU-1194.
RX   PubMed=7881431; DOI=10.1093/hmg/3.12.2255;
RA   Fransen E., Schrander-Stumpel C., Vits L., Coucke P., van Camp G.,
RA   Willems P.J.;
RT   "X-linked hydrocephalus and MASA syndrome present in one family are due to
RT   a single missense mutation in exon 28 of the L1CAM gene.";
RL   Hum. Mol. Genet. 3:2255-2256(1994).
RN   [27]
RP   INVOLVEMENT IN MASA, INVOLVEMENT IN HYCX, VARIANTS HYCX GLN-184 AND
RP   ARG-452, AND VARIANT MASA GLN-210.
RX   PubMed=7920659; DOI=10.1038/ng0794-402;
RA   Jouet M., Rosenthal A., Armstrong G., Macfarlane J., Stevenson R.,
RA   Paterson J., Metzenberg A., Ionasescu V., Temple K., Kenwrick S.;
RT   "X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked
RT   hydrocephalus result from mutations in the L1 gene.";
RL   Nat. Genet. 7:402-407(1994).
RN   [28]
RP   VARIANTS MASA GLN-210 AND ASN-598.
RX   PubMed=7920660; DOI=10.1038/ng0794-408;
RA   Vits L., van Camp G., Coucke P., Fransen E., de Boulle K., Reyniers E.,
RA   Korn B., Poustka A., Wilson G., Schrander-Stumpel C., Winter R.M.,
RA   Schwartz C., Willems P.J.;
RT   "MASA syndrome is due to mutations in the neural cell adhesion gene
RT   L1CAM.";
RL   Nat. Genet. 7:408-413(1994).
RN   [29]
RP   VARIANTS MASA LYS-309 AND LEU-941, AND VARIANTS HYCX SER-9; SER-121;
RP   PHE-768; LEU-941 AND CYS-1070.
RX   PubMed=7762552;
RA   Jouet M., Moncla A., Paterson J., McKeown C., Fryer A., Carpenter N.,
RA   Holmberg E., Wadelius C., Kenwrick S.;
RT   "New domains of neural cell-adhesion molecule L1 implicated in X-linked
RT   hydrocephalus and MASA syndrome.";
RL   Am. J. Hum. Genet. 56:1304-1314(1995).
RN   [30]
RP   VARIANTS HYCX GLN-184; TYR-264; ARG-452 AND LEU-1194, AND VARIANTS MASA
RP   GLN-210; ASN-598 AND LEU-1194.
RX   PubMed=8556302; DOI=10.1159/000472311;
RA   Fransen E., Lemmon V., van Camp G., Vits L., Coucke P., Willems P.J.;
RT   "CRASH syndrome: clinical spectrum of corpus callosum hypoplasia,
RT   retardation, adducted thumbs, spastic paraparesis and hydrocephalus due to
RT   mutations in one single gene, L1.";
RL   Eur. J. Hum. Genet. 3:273-284(1995).
RN   [31]
RP   ERRATUM OF PUBMED:8556302.
RA   Fransen E., Lemmon V., van Camp G., Vits L., Coucke P., Willems P.J.;
RL   Eur. J. Hum. Genet. 4:126-126(1996).
RN   [32]
RP   INVOLVEMENT IN MASA, INVOLVEMENT IN HYCX, VARIANTS HYCX SER-179 AND
RP   ARG-370, AND VARIANTS MASA SER-179 AND ARG-370.
RX   PubMed=7562969; DOI=10.1136/jmg.32.7.549;
RA   Ruiz J.C., Cuppens H., Legius E., Fryns J.-P., Glover T., Marynen P.,
RA   Cassiman J.-J.;
RT   "Mutations in L1-CAM in two families with X linked complicated spastic
RT   paraplegia, MASA syndrome, and HSAS.";
RL   J. Med. Genet. 32:549-552(1995).
RN   [33]
RP   VARIANT HYCX GLU-655.
RX   PubMed=9118141; DOI=10.1007/bf00261591;
RA   Izumoto S., Yamasaki M., Arita N., Hiraga S., Ohnishi T., Fujitani K.,
RA   Sakoda S., Hayakawa T.;
RT   "A new mutation of the L1CAM gene in an X-linked hydrocephalus family.";
RL   Childs Nerv. Syst. 12:742-747(1996).
RN   [34]
RP   VARIANTS HYCX CYS-194 AND LEU-240.
RX   PubMed=8929944; DOI=10.1136/jmg.33.2.103;
RA   Gu S.-M., Orth U., Veske A., Enders H., Kluender K., Schloesser M.,
RA   Engel W., Schwinger E., Gal A.;
RT   "Five novel mutations in the L1CAM gene in families with X linked
RT   hydrocephalus.";
RL   J. Med. Genet. 33:103-106(1996).
RN   [35]
RP   VARIANT MASA PRO-482, VARIANTS HYCX SER-526 DEL; PRO-542 AND THR-741,
RP   VARIANT HYCX/MASA MET-752, AND VARIANT ILE-768.
RX   PubMed=9268105;
RX   DOI=10.1002/(sici)1096-8628(19970822)71:3<336::aid-ajmg15>3.0.co;2-l;
RA   Gu S.-M., Orth U., Zankl M., Schroeder J., Gal A.;
RT   "Molecular analysis of the L1CAM gene in patients with X-linked
RT   hydrocephalus demonstrates eight novel mutations and suggests non-allelic
RT   heterogeneity of the trait.";
RL   Am. J. Med. Genet. 71:336-340(1997).
RN   [36]
RP   VARIANTS MASA ASP-268 AND ASP-426.
RX   PubMed=9300653; DOI=10.1093/hmg/6.10.1625;
RA   Fransen E., Van Camp G., Vits L., Willems P.J.;
RT   "L1-associated diseases: clinical geneticists divide, molecular geneticists
RT   unite.";
RL   Hum. Mol. Genet. 6:1625-1632(1997).
RN   [37]
RP   VARIANTS HYCX GLN-184; 439-VAL--THR-443 DEL; CYS-784 AND 936-LEU--LEU-948
RP   DEL.
RX   PubMed=9195224;
RX   DOI=10.1002/(sici)1098-1004(1997)9:6<512::aid-humu3>3.0.co;2-3;
RA   Macfarlane J.R., Du J.-S., Pepys M.E., Ramsden S., Donnai D., Charlton R.,
RA   Garrett C., Tolmie J., Yates J.R.W., Berry C., Goudie D., Moncla A.,
RA   Lunt P., Hodgson S., Jouet M., Kenwrick S.;
RT   "Nine novel L1 CAM mutations in families with X-linked hydrocephalus.";
RL   Hum. Mutat. 9:512-518(1997).
RN   [38]
RP   VARIANTS MASA ASP-691 AND ARG-698, AND VARIANTS HYCX ARG-698 AND PRO-935.
RX   PubMed=9521424;
RX   DOI=10.1002/(sici)1098-1004(1998)11:3<222::aid-humu7>3.0.co;2-j;
RA   Du Y.-Z., Srivastava A.K., Schwartz C.E.;
RT   "Multiple exon screening using restriction endonuclease fingerprinting
RT   (REF): detection of six novel mutations in the L1 cell adhesion molecule
RT   (L1CAM) gene.";
RL   Hum. Mutat. 11:222-230(1998).
RN   [39]
RP   VARIANT MASA PRO-632.
RX   PubMed=9452110; DOI=10.1002/humu.1380110189;
RA   Vits L., Chitayat D., van Camp G., Holden J.J.A., Fransen E., Willems P.J.;
RT   "Evidence for somatic and germline mosaicism in CRASH syndrome.";
RL   Hum. Mutat. Suppl. 1:S284-S287(1998).
RN   [40]
RP   VARIANTS MASA ARG-335 AND CYS-473, AND VARIANTS HYCX THR-219; ARG-335;
RP   CYS-386; CYS-473 AND LEU-1224.
RX   PubMed=9744477;
RX   DOI=10.1002/(sici)1098-1004(1998)12:4<259::aid-humu7>3.0.co;2-a;
RA   Saugier-Veber P., Martin C., le Meur N., Lyonnet S., Munnich A., David A.,
RA   Henocq A., Heron D., Jonveaux P., Odent S., Manouvrier S., Moncla A.,
RA   Morichon N., Philip N., Satge D., Tosi M., Frebourg T.;
RT   "Identification of novel L1CAM mutations using fluorescence-assisted
RT   mismatch analysis.";
RL   Hum. Mutat. 12:259-266(1998).
RN   [41]
RP   VARIANTS MASA CYS-674 AND ASP-691, AND VARIANT HYCX ARG-698.
RX   PubMed=9832035; DOI=10.1136/jmg.35.11.901;
RA   Michaelis R.C., Du Y.-Z., Schwartz C.E.;
RT   "The site of a missense mutation in the extracellular Ig or FN domains of
RT   L1CAM influences infant mortality and the severity of X linked
RT   hydrocephalus.";
RL   J. Med. Genet. 35:901-904(1998).
RN   [42]
RP   VARIANTS HYCX TRP-184; CYS-335; ILE-408; ASP-421; TYR-497; THR-691 AND
RP   PRO-751, VARIANTS ASN-30; TRP-739 AND GLU-1239, AND VARIANT HYCX/MASA
RP   ARG-370.
RX   PubMed=10797421;
RX   DOI=10.1002/(sici)1096-8628(20000501)92:1<40::aid-ajmg7>3.0.co;2-r;
RA   Finckh U., Schroeder J., Ressler B., Veske A., Gal A.;
RT   "Spectrum and detection rate of L1CAM mutations in isolated and familial
RT   cases with clinically suspected L1-disease.";
RL   Am. J. Med. Genet. 92:40-46(2000).
RN   [43]
RP   VARIANT MASA TYR-202.
RX   PubMed=10805190; DOI=10.1177/088307380001500407;
RA   Sztriha L., Frossard P., Hofstra R.M., Verlind E., Nork M.;
RT   "Novel missense mutation in the L1 gene in a child with corpus callosum
RT   agenesis, retardation, adducted thumbs, spastic paraparesis, and
RT   hydrocephalus.";
RL   J. Child Neurol. 15:239-243(2000).
RN   [44]
RP   VARIANT HYCX/MASA MET-752, AND POSSIBLE INVOLVEMENT IN HIRSCHSPRUNG
RP   DISEASE.
RX   PubMed=11857550; DOI=10.1002/ajmg.10185;
RA   Parisi M.A., Kapur R.P., Neilson I., Hofstra R.M.W., Holloway L.W.,
RA   Michaelis R.C., Leppig K.A.;
RT   "Hydrocephalus and intestinal aganglionosis: is L1CAM a modifier gene in
RT   Hirschsprung disease?";
RL   Am. J. Med. Genet. 108:51-56(2002).
RN   [45]
RP   VARIANT HYCX PRO-415.
RX   PubMed=12435569; DOI=10.1016/s0887-8994(02)00440-x;
RA   Sztriha L., Vos Y.J., Verlind E., Johansen J., Berg B.;
RT   "X-linked hydrocephalus: a novel missense mutation in the L1CAM gene.";
RL   Pediatr. Neurol. 27:293-296(2002).
RN   [46]
RP   CHARACTERIZATION OF VARIANT HYCX TYR-264, SUBCELLULAR LOCATION, AND
RP   GLYCOSYLATION.
RX   PubMed=12514225; DOI=10.1523/jneurosci.23-01-00277.2003;
RA   Ruenker A.E., Bartsch U., Nave K.A., Schachner M.;
RT   "The C264Y missense mutation in the extracellular domain of L1 impairs
RT   protein trafficking in vitro and in vivo.";
RL   J. Neurosci. 23:277-286(2003).
RN   [47]
RP   VARIANT ACCPX LEU-240.
RX   PubMed=16650080; DOI=10.1111/j.1399-0004.2006.00607.x;
RA   Basel-Vanagaite L., Straussberg R., Friez M.J., Inbar D., Korenreich L.,
RA   Shohat M., Schwartz C.E.;
RT   "Expanding the phenotypic spectrum of L1CAM-associated disease.";
RL   Clin. Genet. 69:414-419(2006).
RN   [48]
RP   VARIANT MASA ASN-770.
RX   PubMed=16816908; DOI=10.1007/s10072-006-0610-2;
RA   Simonati A., Boaretto F., Vettori A., Dabrilli P., Criscuolo L.,
RA   Rizzuto N., Mostacciuolo M.L.;
RT   "A novel missense mutation in the L1CAM gene in a boy with L1 disease.";
RL   Neurol. Sci. 27:114-117(2006).
RN   [49]
RP   CHARACTERIZATION OF VARIANTS HYCX GLN-184 AND LEU-1036, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20621658; DOI=10.1016/j.nbd.2010.05.029;
RA   Schaefer M.K., Nam Y.C., Moumen A., Keglowich L., Bouche E., Kueffner M.,
RA   Bock H.H., Rathjen F.G., Raoul C., Frotscher M.;
RT   "L1 syndrome mutations impair neuronal L1 function at different levels by
RT   divergent mechanisms.";
RL   Neurobiol. Dis. 40:222-237(2010).
RN   [50]
RP   VARIANT HYCX ARG-698.
RX   PubMed=22344793; DOI=10.1002/ajmg.a.35244;
RA   Fernandez R.M., Nunez-Torres R., Garcia-Diaz L., de Agustin J.C.,
RA   Antinolo G., Borrego S.;
RT   "Association of X-linked hydrocephalus and Hirschsprung disease: Report of
RT   a new patient with a mutation in the L1CAM gene.";
RL   Am. J. Med. Genet. A 158:816-820(2012).
RN   [51]
RP   CHARACTERIZATION OF VARIANTS MASA GLN-210 AND LYS-309, CHARACTERIZATION OF
RP   VARIANTS HYCX THR-219 AND CYS-264, CHARACTERIZATION OF VARIANT HYCX/MASA
RP   LEU-941, AND SUBCELLULAR LOCATION.
RX   PubMed=22973895; DOI=10.1111/jnc.12015;
RA   Tagliavacca L., Colombo F., Racchetti G., Meldolesi J.;
RT   "L1CAM and its cell-surface mutants: new mechanisms and effects relevant to
RT   the physiology and pathology of neural cells.";
RL   J. Neurochem. 124:397-409(2013).
RN   [52]
RP   CHARACTERIZATION OF VARIANT VAL-120, CHARACTERIZATION OF VARIANTS MASA
RP   GLN-210 AND LYS-309, CHARACTERIZATION OF VARIANTS HYCX GLN-184; TYR-264 AND
RP   CYS-1070, AND MUTAGENESIS OF 1147-LYS--VAL-1153.
RX   PubMed=24155914; DOI=10.1371/journal.pone.0076974;
RA   Kudumala S., Freund J., Hortsch M., Godenschwege T.A.;
RT   "Differential effects of human L1CAM mutations on complementing guidance
RT   and synaptic defects in Drosophila melanogaster.";
RL   PLoS ONE 8:E76974-E76974(2013).
RN   [53]
RP   VARIANT 789-GLN--GLU-1257 DEL, CHARACTERIZATION OF VARIANTS ASN-37; MET-38
RP   AND ILE-172, CHARACTERIZATION OF VARIANT MASA TYR-202, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=26891472; DOI=10.1111/cge.12763;
RA   Christaller W.A., Vos Y., Gebre-Medhin S., Hofstra R.M., Schaefer M.K.;
RT   "L1 syndrome diagnosis complemented with functional analysis of L1CAM
RT   variants located to the two N-terminal Ig-like domains.";
RL   Clin. Genet. 91:115-120(2017).
CC   -!- FUNCTION: Neural cell adhesion molecule involved in the dynamics of
CC       cell adhesion and in the generation of transmembrane signals at
CC       tyrosine kinase receptors. During brain development, critical in
CC       multiple processes, including neuronal migration, axonal growth and
CC       fasciculation, and synaptogenesis. In the mature brain, plays a role in
CC       the dynamics of neuronal structure and function, including synaptic
CC       plasticity. {ECO:0000269|PubMed:20621658, ECO:0000305}.
CC   -!- SUBUNIT: Interacts with SHTN1; the interaction occurs in axonal growth
CC       cones (By similarity). Interacts with isoform 2 of BSG (By similarity).
CC       {ECO:0000250|UniProtKB:P11627, ECO:0000250|UniProtKB:Q05695}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12514225,
CC       ECO:0000269|PubMed:20621658, ECO:0000269|PubMed:22973895,
CC       ECO:0000269|PubMed:26891472}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:Q05695}. Cell projection, growth cone
CC       {ECO:0000250|UniProtKB:Q05695}. Cell projection, axon
CC       {ECO:0000269|PubMed:20621658}. Cell projection, dendrite.
CC       Note=Colocalized with SHTN1 in close apposition with actin filaments in
CC       filopodia and lamellipodia of axonalne growth cones of hippocampal
CC       neurons (By similarity). In neurons, detected predominantly in axons
CC       and cell body, weak localization to dendrites (PubMed:20621658).
CC       {ECO:0000250|UniProtKB:Q05695, ECO:0000269|PubMed:20621658}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P32004-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P32004-2; Sequence=VSP_002591;
CC       Name=3;
CC         IsoId=P32004-3; Sequence=VSP_046317, VSP_002591;
CC   -!- DISEASE: Hydrocephalus, congenital, X-linked (HYCX) [MIM:307000]: An X-
CC       linked recessive form of congenital hydrocephalus, a disease
CC       characterized by in utero onset of enlarged ventricles due to
CC       accumulation of ventricular cerebrospinal fluid. HYCX is the most
CC       common inherited form and occurs in approximately 1/30000 male births.
CC       The primary diagnostic criteria of intellectual disability and enlarged
CC       cerebral ventricles are often accompanied by spastic paraparesis and
CC       adducted thumbs and, occasionally, visual defects or seizures. The most
CC       severe cases die pre- or perinatally with gross hydrocephalus and
CC       enlarged head circumference. Stenosis of the aqueduct of Sylvius is
CC       frequently associated with the disorder. {ECO:0000269|PubMed:10797421,
CC       ECO:0000269|PubMed:11857550, ECO:0000269|PubMed:12435569,
CC       ECO:0000269|PubMed:12514225, ECO:0000269|PubMed:19846429,
CC       ECO:0000269|PubMed:20621658, ECO:0000269|PubMed:22344793,
CC       ECO:0000269|PubMed:22973895, ECO:0000269|PubMed:24155914,
CC       ECO:0000269|PubMed:7562969, ECO:0000269|PubMed:7762552,
CC       ECO:0000269|PubMed:7881431, ECO:0000269|PubMed:7920659,
CC       ECO:0000269|PubMed:8401576, ECO:0000269|PubMed:8556302,
CC       ECO:0000269|PubMed:8929944, ECO:0000269|PubMed:9118141,
CC       ECO:0000269|PubMed:9195224, ECO:0000269|PubMed:9268105,
CC       ECO:0000269|PubMed:9521424, ECO:0000269|PubMed:9744477,
CC       ECO:0000269|PubMed:9832035}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry. L1CAM mutations have also
CC       been found in few patients affected by hydrocephalus with Hirschsprung
CC       disease, suggesting a role of this gene acting either in a direct or
CC       indirect way in the pathogenesis of Hirschsprung disease
CC       (PubMed:22344793). {ECO:0000269|PubMed:22344793}.
CC   -!- DISEASE: MASA syndrome (MASA) [MIM:303350]: An X-linked recessive
CC       syndrome with a highly variable clinical spectrum. Main clinical
CC       features include spasticity and hyperreflexia of lower limbs, shuffling
CC       gait, intellectual disability, aphasia and adducted thumbs. The
CC       features of spasticity have been referred to as complicated spastic
CC       paraplegia type 1 (SPG1). Some patients manifest corpus callosum
CC       hypoplasia and hydrocephalus. Inter- and intrafamilial variability is
CC       very wide, such that patients with hydrocephalus, MASA, SPG1, and
CC       agenesis of corpus callosum can be present within the same family.
CC       {ECO:0000269|PubMed:10797421, ECO:0000269|PubMed:10805190,
CC       ECO:0000269|PubMed:11857550, ECO:0000269|PubMed:16816908,
CC       ECO:0000269|PubMed:19846429, ECO:0000269|PubMed:22344793,
CC       ECO:0000269|PubMed:22973895, ECO:0000269|PubMed:24155914,
CC       ECO:0000269|PubMed:26891472, ECO:0000269|PubMed:7562969,
CC       ECO:0000269|PubMed:7762552, ECO:0000269|PubMed:7881431,
CC       ECO:0000269|PubMed:7920659, ECO:0000269|PubMed:7920660,
CC       ECO:0000269|PubMed:8556302, ECO:0000269|PubMed:9268105,
CC       ECO:0000269|PubMed:9300653, ECO:0000269|PubMed:9452110,
CC       ECO:0000269|PubMed:9521424, ECO:0000269|PubMed:9744477,
CC       ECO:0000269|PubMed:9832035}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in L1CAM may contribute to Hirschsprung disease
CC       by modifying the effects of Hirschsprung disease-associated genes to
CC       cause intestinal aganglionosis. {ECO:0000269|PubMed:11857550}.
CC   -!- DISEASE: Agenesis of the corpus callosum, X-linked, partial (ACCPX)
CC       [MIM:304100]: A syndrome characterized by partial corpus callosum
CC       agenesis, hypoplasia of inferior vermis and cerebellum, intellectual
CC       disability, seizures and spasticity. Other features include
CC       microcephaly, unusual facies, and Hirschsprung disease in some
CC       patients. {ECO:0000269|PubMed:16650080}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in L1CAM are associated with a wide phenotypic
CC       spectrum which varies from severe hydrocephalus and prenatal death
CC       (HYCX) to a milder phenotype (MASA). These variations may even occur
CC       within the same family. Due to the overlap of phenotypes between HYCX
CC       and MASA, many authors use the general concept of L1 syndrome which
CC       covers both ends of the spectrum. {ECO:0000269|PubMed:19846429,
CC       ECO:0000269|PubMed:22222883, ECO:0000269|PubMed:26891472}.
CC   -!- SIMILARITY: Belongs to the immunoglobulin superfamily.
CC       L1/neurofascin/NgCAM family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/44110/L1CAM";
CC   -!- WEB RESOURCE: Name=L1CAM; Note=L1CAM mutation Web Page;
CC       URL="http://www.l1cammutationdatabase.info/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X59847; CAA42508.1; -; mRNA.
DR   EMBL; M77640; AAC14352.1; -; mRNA.
DR   EMBL; M74387; AAA59476.1; -; mRNA.
DR   EMBL; U52111; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z29373; CAA82564.1; -; Genomic_DNA.
DR   EMBL; EF506611; ABP88252.1; -; mRNA.
DR   EMBL; U52112; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471172; EAW72787.1; -; Genomic_DNA.
DR   EMBL; BC025843; AAH25843.1; -; mRNA.
DR   EMBL; BC126229; AAI26230.1; -; mRNA.
DR   EMBL; BC136447; AAI36448.1; -; mRNA.
DR   EMBL; M55271; AAA36353.1; ALT_SEQ; mRNA.
DR   EMBL; X58775; CAA41576.1; -; Genomic_DNA.
DR   EMBL; X58776; CAB37831.1; -; mRNA.
DR   CCDS; CCDS14733.1; -. [P32004-1]
DR   CCDS; CCDS14734.1; -. [P32004-2]
DR   CCDS; CCDS48192.1; -. [P32004-3]
DR   PIR; A41060; A41060.
DR   RefSeq; NP_000416.1; NM_000425.4. [P32004-1]
DR   RefSeq; NP_001137435.1; NM_001143963.2. [P32004-3]
DR   RefSeq; NP_001265045.1; NM_001278116.1. [P32004-1]
DR   RefSeq; NP_076493.1; NM_024003.3. [P32004-2]
DR   PDB; 8AFO; X-ray; 1.99 A; A=712-917.
DR   PDB; 8AFP; X-ray; 3.00 A; A=712-917.
DR   PDBsum; 8AFO; -.
DR   PDBsum; 8AFP; -.
DR   AlphaFoldDB; P32004; -.
DR   SASBDB; P32004; -.
DR   SMR; P32004; -.
DR   BioGRID; 110094; 59.
DR   CORUM; P32004; -.
DR   ELM; P32004; -.
DR   IntAct; P32004; 11.
DR   MINT; P32004; -.
DR   STRING; 9606.ENSP00000359077; -.
DR   DrugBank; DB00898; Ethanol.
DR   GlyConnect; 1547; 18 N-Linked glycans (4 sites).
DR   GlyCosmos; P32004; 21 sites, 21 glycans.
DR   GlyGen; P32004; 22 sites, 20 N-linked glycans (4 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; P32004; -.
DR   PhosphoSitePlus; P32004; -.
DR   SwissPalm; P32004; -.
DR   BioMuta; L1CAM; -.
DR   DMDM; 1705571; -.
DR   EPD; P32004; -.
DR   jPOST; P32004; -.
DR   MassIVE; P32004; -.
DR   MaxQB; P32004; -.
DR   PaxDb; P32004; -.
DR   PeptideAtlas; P32004; -.
DR   ProteomicsDB; 33733; -.
DR   ProteomicsDB; 54830; -. [P32004-1]
DR   ProteomicsDB; 54831; -. [P32004-2]
DR   ABCD; P32004; 16 sequenced antibodies.
DR   Antibodypedia; 449; 1332 antibodies from 45 providers.
DR   DNASU; 3897; -.
DR   Ensembl; ENST00000361699.8; ENSP00000355380.4; ENSG00000198910.14. [P32004-2]
DR   Ensembl; ENST00000361981.7; ENSP00000354712.3; ENSG00000198910.14. [P32004-3]
DR   Ensembl; ENST00000370055.5; ENSP00000359072.1; ENSG00000198910.14. [P32004-3]
DR   Ensembl; ENST00000370060.7; ENSP00000359077.1; ENSG00000198910.14. [P32004-1]
DR   GeneID; 3897; -.
DR   KEGG; hsa:3897; -.
DR   MANE-Select; ENST00000370060.7; ENSP00000359077.1; NM_001278116.2; NP_001265045.1.
DR   UCSC; uc004fjc.5; human. [P32004-1]
DR   AGR; HGNC:6470; -.
DR   CTD; 3897; -.
DR   DisGeNET; 3897; -.
DR   GeneCards; L1CAM; -.
DR   GeneReviews; L1CAM; -.
DR   HGNC; HGNC:6470; L1CAM.
DR   HPA; ENSG00000198910; Tissue enhanced (brain, intestine).
DR   MalaCards; L1CAM; -.
DR   MIM; 303350; phenotype.
DR   MIM; 304100; phenotype.
DR   MIM; 307000; phenotype.
DR   MIM; 308840; gene.
DR   neXtProt; NX_P32004; -.
DR   OpenTargets; ENSG00000198910; -.
DR   Orphanet; 2182; Hydrocephalus with stenosis of the aqueduct of Sylvius.
DR   Orphanet; 2466; MASA syndrome.
DR   Orphanet; 1497; X-linked complicated corpus callosum dysgenesis.
DR   Orphanet; 306617; X-linked complicated spastic paraplegia type 1.
DR   PharmGKB; PA30259; -.
DR   VEuPathDB; HostDB:ENSG00000198910; -.
DR   eggNOG; KOG3513; Eukaryota.
DR   GeneTree; ENSGT00940000157506; -.
DR   HOGENOM; CLU_005756_1_1_1; -.
DR   InParanoid; P32004; -.
DR   OMA; GARTIIQ; -.
DR   OrthoDB; 2912783at2759; -.
DR   PhylomeDB; P32004; -.
DR   TreeFam; TF351098; -.
DR   PathwayCommons; P32004; -.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-373760; L1CAM interactions.
DR   Reactome; R-HSA-437239; Recycling pathway of L1.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   SignaLink; P32004; -.
DR   SIGNOR; P32004; -.
DR   BioGRID-ORCS; 3897; 8 hits in 771 CRISPR screens.
DR   ChiTaRS; L1CAM; human.
DR   GeneWiki; L1_(protein); -.
DR   GenomeRNAi; 3897; -.
DR   Pharos; P32004; Tbio.
DR   PRO; PR:P32004; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P32004; protein.
DR   Bgee; ENSG00000198910; Expressed in cortical plate and 160 other tissues.
DR   ExpressionAtlas; P32004; baseline and differential.
DR   Genevisible; P32004; HS.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0044295; C:axonal growth cone; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0008046; F:axon guidance receptor activity; IBA:GO_Central.
DR   GO; GO:0019904; F:protein domain specific binding; IDA:CAFA.
DR   GO; GO:0061564; P:axon development; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IDA:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; NAS:ProtInc.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IBA:GO_Central.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0031175; P:neuron projection development; IDA:UniProtKB.
DR   GO; GO:0045773; P:positive regulation of axon extension; ISS:UniProtKB.
DR   GO; GO:0050808; P:synapse organization; IDA:UniProtKB.
DR   CDD; cd00063; FN3; 4.
DR   CDD; cd05876; Ig3_L1-CAM; 1.
DR   CDD; cd05867; Ig4_L1-CAM_like; 1.
DR   CDD; cd05845; IgI_2_L1-CAM_like; 1.
DR   DisProt; DP00666; -.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 10.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR026966; Neurofascin/L1/NrCAM_C.
DR   PANTHER; PTHR44170:SF6; PROTEIN SAX-3; 1.
DR   PANTHER; PTHR44170; PROTEIN SIDEKICK; 1.
DR   Pfam; PF13882; Bravo_FIGEY; 1.
DR   Pfam; PF00041; fn3; 4.
DR   Pfam; PF07679; I-set; 3.
DR   Pfam; PF13927; Ig_3; 2.
DR   SMART; SM00060; FN3; 4.
DR   SMART; SM00409; IG; 6.
DR   SMART; SM00408; IGc2; 5.
DR   SUPFAM; SSF49265; Fibronectin type III; 2.
DR   SUPFAM; SSF48726; Immunoglobulin; 6.
DR   PROSITE; PS50853; FN3; 5.
DR   PROSITE; PS50835; IG_LIKE; 6.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Cell membrane;
KW   Cell projection; Developmental protein; Differentiation;
KW   Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein;
KW   Hereditary spastic paraplegia; Hirschsprung disease; Immunoglobulin domain;
KW   Intellectual disability; Membrane; Neurodegeneration; Neurogenesis;
KW   Phosphoprotein; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000269|PubMed:3136168"
FT   CHAIN           20..1257
FT                   /note="Neural cell adhesion molecule L1"
FT                   /id="PRO_0000015022"
FT   TOPO_DOM        20..1120
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1121..1143
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1144..1257
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          35..125
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          139..226
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          240..328
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          333..420
FT                   /note="Ig-like C2-type 4"
FT   DOMAIN          425..507
FT                   /note="Ig-like C2-type 5"
FT   DOMAIN          518..607
FT                   /note="Ig-like C2-type 6"
FT   DOMAIN          615..712
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          717..810
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          814..916
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          920..1015
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1016..1115
FT                   /note="Fibronectin type-III 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   REGION          698..725
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1176..1207
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1226..1257
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           554..556
FT                   /note="Cell attachment site"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         1163
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         1178
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11627"
FT   MOD_RES         1181
FT                   /note="Phosphoserine; by CaMK2"
FT                   /evidence="ECO:0000269|PubMed:8592152"
FT   MOD_RES         1194
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         1243
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1244
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11627"
FT   MOD_RES         1248
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   CARBOHYD        100
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        203
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        247
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        294
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        433
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        479
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        490
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        505
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        588
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        671
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        726
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        777
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        825
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        849
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        876
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        979
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1022
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1030
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1071
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1105
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        57..114
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        158..209
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        264..312
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        354..404
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        448..497
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        539..591
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         26..31
FT                   /note="YEGHHV -> L (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_046317"
FT   VAR_SEQ         1177..1180
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1627459, ECO:0000303|Ref.6"
FT                   /id="VSP_002591"
FT   VARIANT         9
FT                   /note="W -> S (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:7762552"
FT                   /id="VAR_003921"
FT   VARIANT         26..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078350"
FT   VARIANT         30
FT                   /note="H -> N"
FT                   /evidence="ECO:0000269|PubMed:10797421"
FT                   /id="VAR_030403"
FT   VARIANT         37
FT                   /note="I -> N (probable disease-associated variant found in
FT                   L1 syndrome; loss of localization at the cell surface;
FT                   retention in the endoplasmic reticulum; loss of homophilic
FT                   interactions at the cell surface)"
FT                   /evidence="ECO:0000269|PubMed:19846429,
FT                   ECO:0000269|PubMed:26891472"
FT                   /id="VAR_078351"
FT   VARIANT         38
FT                   /note="T -> M (no effect on localization at the cell
FT                   surface; dbSNP:rs201151358)"
FT                   /evidence="ECO:0000269|PubMed:19846429,
FT                   ECO:0000269|PubMed:26891472"
FT                   /id="VAR_078352"
FT   VARIANT         66..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078353"
FT   VARIANT         109..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078354"
FT   VARIANT         120
FT                   /note="L -> V (no effect on axon guidance activity, nor on
FT                   synapse formation, when assayed in a heterologous system;
FT                   dbSNP:rs796052697)"
FT                   /evidence="ECO:0000269|PubMed:24155914"
FT                   /id="VAR_078355"
FT   VARIANT         121
FT                   /note="G -> S (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:7762552"
FT                   /id="VAR_003922"
FT   VARIANT         133..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078356"
FT   VARIANT         138..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078357"
FT   VARIANT         172
FT                   /note="M -> I (probable disease-associated variant found in
FT                   a patient with L1 syndrome; loss of homophilic interactions
FT                   at the cell surface; no effect on the localization at the
FT                   cell surface)"
FT                   /evidence="ECO:0000269|PubMed:19846429,
FT                   ECO:0000269|PubMed:26891472"
FT                   /id="VAR_078358"
FT   VARIANT         179
FT                   /note="I -> S (in HYCX and MASA; dbSNP:rs137852523)"
FT                   /evidence="ECO:0000269|PubMed:19846429,
FT                   ECO:0000269|PubMed:7562969"
FT                   /id="VAR_003923"
FT   VARIANT         184
FT                   /note="R -> G (probable disease-associated variant found in
FT                   L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078359"
FT   VARIANT         184
FT                   /note="R -> Q (in HYCX; severe; reduced axon arborization;
FT                   partial loss of localization at the cell surface; retention
FT                   in the endoplasmic reticulum; in neurons, restricted to
FT                   cell bodies and proximal segments of processes; loss of
FT                   axon guidance and of proper synapse formation, when assayed
FT                   in a heterologous system; dbSNP:rs137852521)"
FT                   /evidence="ECO:0000269|PubMed:19846429,
FT                   ECO:0000269|PubMed:20621658, ECO:0000269|PubMed:24155914,
FT                   ECO:0000269|PubMed:7920659, ECO:0000269|PubMed:8556302,
FT                   ECO:0000269|PubMed:9195224"
FT                   /id="VAR_003924"
FT   VARIANT         184
FT                   /note="R -> W (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:10797421"
FT                   /id="VAR_030404"
FT   VARIANT         187..198
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078360"
FT   VARIANT         194
FT                   /note="Y -> C (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:8929944"
FT                   /id="VAR_003925"
FT   VARIANT         202
FT                   /note="D -> Y (in MASA; loss of homophilic interactions at
FT                   the cell surface; no effect on localization at the cell
FT                   surface)"
FT                   /evidence="ECO:0000269|PubMed:10805190,
FT                   ECO:0000269|PubMed:19846429, ECO:0000269|PubMed:26891472"
FT                   /id="VAR_030405"
FT   VARIANT         210
FT                   /note="H -> Q (in MASA; decrease in cell-matrix adhesion;
FT                   decreased cell migration; loss of axon guidance and of
FT                   proper synapse formation, when assayed in a heterologous
FT                   system; no effect on the localization at the cell surface;
FT                   no effect on cell proliferation, when transfected in
FT                   pheochromocytoma PC12 cells; no effect on neurite
FT                   outgrowth, when assayed in NGF-treated pheochromocytoma
FT                   PC12 cells; dbSNP:rs28933683)"
FT                   /evidence="ECO:0000269|PubMed:22973895,
FT                   ECO:0000269|PubMed:24155914, ECO:0000269|PubMed:7920659,
FT                   ECO:0000269|PubMed:7920660, ECO:0000269|PubMed:8556302"
FT                   /id="VAR_003926"
FT   VARIANT         219
FT                   /note="I -> T (in HYCX; decrease in cell-matrix adhesion;
FT                   decreased cell migration; no effect on the localization at
FT                   the cell surface; no effect on cell proliferation, when
FT                   transfected in pheochromocytoma PC12 cells; no effect on
FT                   neurite outgrowth, when assayed in NGF-treated
FT                   pheochromocytoma PC12 cells)"
FT                   /evidence="ECO:0000269|PubMed:22973895,
FT                   ECO:0000269|PubMed:9744477"
FT                   /id="VAR_003927"
FT   VARIANT         240
FT                   /note="P -> L (in HYCX and ACCPX; dbSNP:rs137852526)"
FT                   /evidence="ECO:0000269|PubMed:16650080,
FT                   ECO:0000269|PubMed:8929944"
FT                   /id="VAR_003928"
FT   VARIANT         254
FT                   /note="A -> D (probable disease-associated variant found in
FT                   L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078361"
FT   VARIANT         264
FT                   /note="C -> Y (in HYCX; severe; loss of localization to the
FT                   cell surface; retention in the endoplasmic reticulum; loss
FT                   of axon guidance, when assayed in a heterologous system;
FT                   dbSNP:rs137852518)"
FT                   /evidence="ECO:0000269|PubMed:12514225,
FT                   ECO:0000269|PubMed:22973895, ECO:0000269|PubMed:24155914,
FT                   ECO:0000269|PubMed:8401576, ECO:0000269|PubMed:8556302"
FT                   /id="VAR_003929"
FT   VARIANT         268
FT                   /note="G -> D (in MASA)"
FT                   /evidence="ECO:0000269|PubMed:9300653"
FT                   /id="VAR_030406"
FT   VARIANT         276
FT                   /note="W -> R (probable disease-associated variant found in
FT                   L1 syndrome; dbSNP:rs1131691900)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078362"
FT   VARIANT         309
FT                   /note="E -> K (in MASA; decrease in neurite outgrowth, when
FT                   assayed in NGF-treated pheochromocytoma PC12 cells;
FT                   decrease in cell-matrix adhesion; decreased cell migration;
FT                   no effect on axon guidance, on subcellular location to
FT                   synaptic terminals, nor on proper synapse formation, when
FT                   assayed in a heterologous system; no effect on the
FT                   localization at the cell surface; no effect on cell
FT                   proliferation, when transfected in pheochromocytoma PC12
FT                   cells; dbSNP:rs367665974)"
FT                   /evidence="ECO:0000269|PubMed:22973895,
FT                   ECO:0000269|PubMed:24155914, ECO:0000269|PubMed:7762552"
FT                   /id="VAR_003930"
FT   VARIANT         313
FT                   /note="L -> P (probable disease-associated variant found in
FT                   L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078363"
FT   VARIANT         335
FT                   /note="W -> C (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:10797421"
FT                   /id="VAR_030407"
FT   VARIANT         335
FT                   /note="W -> R (in HYCX and MASA; also in a patient with
FT                   hydrocephalus and Hirschsprung disease)"
FT                   /evidence="ECO:0000269|PubMed:19846429,
FT                   ECO:0000269|PubMed:9744477"
FT                   /id="VAR_003931"
FT   VARIANT         366..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078364"
FT   VARIANT         369
FT                   /note="N -> K (probable disease-associated variant found in
FT                   L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078365"
FT   VARIANT         370
FT                   /note="G -> R (in HYCX and MASA; dbSNP:rs137852524)"
FT                   /evidence="ECO:0000269|PubMed:10797421,
FT                   ECO:0000269|PubMed:7562969"
FT                   /id="VAR_003932"
FT   VARIANT         386
FT                   /note="R -> C (in HYCX; dbSNP:rs1557092299)"
FT                   /evidence="ECO:0000269|PubMed:9744477"
FT                   /id="VAR_003933"
FT   VARIANT         408
FT                   /note="N -> I (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:10797421"
FT                   /id="VAR_030408"
FT   VARIANT         415
FT                   /note="A -> P (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:12435569,
FT                   ECO:0000269|PubMed:19846429"
FT                   /id="VAR_027512"
FT   VARIANT         421
FT                   /note="V -> D (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:10797421"
FT                   /id="VAR_030409"
FT   VARIANT         423..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078366"
FT   VARIANT         426
FT                   /note="A -> D (in MASA)"
FT                   /evidence="ECO:0000269|PubMed:9300653"
FT                   /id="VAR_030410"
FT   VARIANT         439..443
FT                   /note="Missing (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:9195224"
FT                   /id="VAR_003934"
FT   VARIANT         452
FT                   /note="G -> R (in HYCX; severe; dbSNP:rs137852520)"
FT                   /evidence="ECO:0000269|PubMed:7920659,
FT                   ECO:0000269|PubMed:8556302"
FT                   /id="VAR_003935"
FT   VARIANT         473
FT                   /note="R -> C (in HYCX and MASA; dbSNP:rs886039408)"
FT                   /evidence="ECO:0000269|PubMed:9744477"
FT                   /id="VAR_003936"
FT   VARIANT         480
FT                   /note="G -> R (probable disease-associated variant found in
FT                   L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078367"
FT   VARIANT         482
FT                   /note="L -> P (in MASA; dbSNP:rs1064794246)"
FT                   /evidence="ECO:0000269|PubMed:9268105"
FT                   /id="VAR_030411"
FT   VARIANT         497
FT                   /note="C -> Y (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:10797421"
FT                   /id="VAR_030412"
FT   VARIANT         516
FT                   /note="D -> N (found in a patient with L1 syndrome; unknown
FT                   pathological significance; dbSNP:rs782367931)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078368"
FT   VARIANT         516
FT                   /note="D -> Y (found in a patient with L1 syndrome; unknown
FT                   pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078369"
FT   VARIANT         525
FT                   /note="R -> H (found in a patient with L1 syndrome; unknown
FT                   pathological significance; dbSNP:rs782401498)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078370"
FT   VARIANT         526
FT                   /note="Missing (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:9268105"
FT                   /id="VAR_030413"
FT   VARIANT         542
FT                   /note="S -> P (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:9268105"
FT                   /id="VAR_030414"
FT   VARIANT         598
FT                   /note="D -> N (in MASA; dbSNP:rs137852519)"
FT                   /evidence="ECO:0000269|PubMed:7920660,
FT                   ECO:0000269|PubMed:8556302"
FT                   /id="VAR_003937"
FT   VARIANT         627
FT                   /note="T -> M (in dbSNP:rs398123360)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078371"
FT   VARIANT         632
FT                   /note="R -> P (in MASA)"
FT                   /evidence="ECO:0000269|PubMed:9452110"
FT                   /id="VAR_003938"
FT   VARIANT         635
FT                   /note="W -> C (probable disease-associated variant found in
FT                   L1 syndrome; loss of localization at the cell surface;
FT                   retention in the endoplasmic reticulum; loss of transport
FT                   into axons; loss of neurite outgrowth; loss of cell-cell
FT                   adhesion)"
FT                   /evidence="ECO:0000269|PubMed:22222883"
FT                   /id="VAR_078372"
FT   VARIANT         645
FT                   /note="I -> P (probable disease-associated variant found in
FT                   L1 syndrome; requires 2 nucleotide substitutions)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078373"
FT   VARIANT         655
FT                   /note="K -> E (in HYCX; dbSNP:rs1375788131)"
FT                   /evidence="ECO:0000269|PubMed:9118141"
FT                   /id="VAR_030415"
FT   VARIANT         662..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078374"
FT   VARIANT         674
FT                   /note="S -> C (in MASA; associated with callosal agenesis)"
FT                   /evidence="ECO:0000269|PubMed:9832035"
FT                   /id="VAR_027513"
FT   VARIANT         691
FT                   /note="A -> D (in MASA; associated with callosal agenesis)"
FT                   /evidence="ECO:0000269|PubMed:9521424,
FT                   ECO:0000269|PubMed:9832035"
FT                   /id="VAR_003939"
FT   VARIANT         691
FT                   /note="A -> T (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:10797421"
FT                   /id="VAR_030416"
FT   VARIANT         698
FT                   /note="G -> R (in HYCX and MASA; associated with callosal
FT                   agenesis; also found in a patient affected by hydrocephalus
FT                   with Hirschsprung disease; dbSNP:rs886039409)"
FT                   /evidence="ECO:0000269|PubMed:22344793,
FT                   ECO:0000269|PubMed:9521424, ECO:0000269|PubMed:9832035"
FT                   /id="VAR_003940"
FT   VARIANT         714
FT                   /note="P -> S (probable disease-associated variant found in
FT                   L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078375"
FT   VARIANT         739
FT                   /note="R -> W (in dbSNP:rs142424573)"
FT                   /evidence="ECO:0000269|PubMed:10797421"
FT                   /id="VAR_030417"
FT   VARIANT         741
FT                   /note="M -> T (in HYCX; dbSNP:rs1557091083)"
FT                   /evidence="ECO:0000269|PubMed:9268105"
FT                   /id="VAR_030418"
FT   VARIANT         751
FT                   /note="R -> P (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:10797421"
FT                   /id="VAR_030419"
FT   VARIANT         752
FT                   /note="V -> M (in HYCX and MASA; also found in a patient
FT                   with the diagnosis of L1 syndrome; also in a patient with
FT                   hydrocephalus and Hirschsprung disease; dbSNP:rs137852525)"
FT                   /evidence="ECO:0000269|PubMed:11857550,
FT                   ECO:0000269|PubMed:19846429, ECO:0000269|PubMed:9268105"
FT                   /id="VAR_014421"
FT   VARIANT         754
FT                   /note="W -> R (probable disease-associated variant found in
FT                   L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078376"
FT   VARIANT         760..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078377"
FT   VARIANT         768
FT                   /note="V -> F (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:7762552"
FT                   /id="VAR_003941"
FT   VARIANT         768
FT                   /note="V -> I (decreased cell-cell adhesion; no effect on
FT                   subcellular localization; no effect on neurite outgrowth;
FT                   dbSNP:rs36021462)"
FT                   /evidence="ECO:0000269|PubMed:22222883,
FT                   ECO:0000269|PubMed:9268105"
FT                   /id="VAR_030420"
FT   VARIANT         770
FT                   /note="D -> N (in MASA; associated with callosal agenesis;
FT                   dbSNP:rs148516831)"
FT                   /evidence="ECO:0000269|PubMed:16816908"
FT                   /id="VAR_027514"
FT   VARIANT         784
FT                   /note="Y -> C (in HYCX; dbSNP:rs797045674)"
FT                   /evidence="ECO:0000269|PubMed:9195224"
FT                   /id="VAR_003942"
FT   VARIANT         789..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429,
FT                   ECO:0000269|PubMed:26891472"
FT                   /id="VAR_078378"
FT   VARIANT         811..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078379"
FT   VARIANT         891..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078380"
FT   VARIANT         901..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078381"
FT   VARIANT         935
FT                   /note="L -> P (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:9521424"
FT                   /id="VAR_003943"
FT   VARIANT         936..948
FT                   /note="Missing (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:9195224"
FT                   /id="VAR_003944"
FT   VARIANT         941
FT                   /note="P -> L (in HYCX and MASA; decrease in neurite
FT                   outgrowth, when assayed in NGF-treated pheochromocytoma
FT                   PC12 cells; decrease in cell-matrix adhesion; decreased
FT                   cell migration; no effect on the localization at the cell
FT                   surface; no effect on cell proliferation, when transfected
FT                   in pheochromocytoma PC12 cells)"
FT                   /evidence="ECO:0000269|PubMed:22973895,
FT                   ECO:0000269|PubMed:7762552"
FT                   /id="VAR_003945"
FT   VARIANT         958
FT                   /note="L -> V (in dbSNP:rs35902890)"
FT                   /id="VAR_059413"
FT   VARIANT         1036
FT                   /note="W -> L (in HYCX; partial loss of localization at the
FT                   cell surface; retention in the endoplasmic reticulum; in
FT                   neurons, partial loss of localization to axons, but
FT                   enriched on proximal dendrites)"
FT                   /evidence="ECO:0000269|PubMed:20621658"
FT                   /id="VAR_078382"
FT   VARIANT         1064..1257
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078383"
FT   VARIANT         1070
FT                   /note="Y -> C (in HYCX; partial loss of axon guidance and
FT                   loss of proper synapse formation, when assayed in a
FT                   heterologous system)"
FT                   /evidence="ECO:0000269|PubMed:24155914,
FT                   ECO:0000269|PubMed:7762552"
FT                   /id="VAR_003946"
FT   VARIANT         1071
FT                   /note="Missing (probable disease-associated variant found
FT                   in L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078384"
FT   VARIANT         1080
FT                   /note="L -> Q (probable disease-associated variant found in
FT                   L1 syndrome)"
FT                   /evidence="ECO:0000269|PubMed:19846429"
FT                   /id="VAR_078385"
FT   VARIANT         1194
FT                   /note="S -> L (in HYCX and MASA; dbSNP:rs137852522)"
FT                   /evidence="ECO:0000269|PubMed:7881431,
FT                   ECO:0000269|PubMed:8556302"
FT                   /id="VAR_003947"
FT   VARIANT         1224
FT                   /note="S -> L (in HYCX)"
FT                   /evidence="ECO:0000269|PubMed:9744477"
FT                   /id="VAR_003948"
FT   VARIANT         1239
FT                   /note="G -> E"
FT                   /evidence="ECO:0000269|PubMed:10797421"
FT                   /id="VAR_030421"
FT   MUTAGEN         1147..1153
FT                   /note="KGGKYSV->AGGAASA: Loss of axon guidance, when
FT                   assayed in a heterologous system, but normal synapse
FT                   formation."
FT                   /evidence="ECO:0000269|PubMed:24155914"
FT   CONFLICT        4
FT                   /note="A -> V (in Ref. 1; CAA42508)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        216
FT                   /note="T -> I (in Ref. 1; CAA42508)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        250
FT                   /note="S -> T (in Ref. 1; CAA42508)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        276..277
FT                   /note="WL -> SV (in Ref. 1; CAA42508)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        288
FT                   /note="V -> A (in Ref. 6; ABP88252)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        357
FT                   /note="Q -> E (in Ref. 1; CAA42508)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        515
FT                   /note="K -> T (in Ref. 6; ABP88252)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        626
FT                   /note="L -> V (in Ref. 1; CAA42508)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        660
FT                   /note="E -> G (in Ref. 6; ABP88252)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        936
FT                   /note="L -> V (in Ref. 12; CAB37831)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1116..1117
FT                   /note="GF -> WLC (in Ref. 13; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1164
FT                   /note="E -> V (in Ref. 6; ABP88252)"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         P32004-2:1177
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         P32004-3:1172
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
SQ   SEQUENCE   1257 AA;  140003 MW;  5EDD764DA86C0E63 CRC64;
     MVVALRYVWP LLLCSPCLLI QIPEEYEGHH VMEPPVITEQ SPRRLVVFPT DDISLKCEAS
     GKPEVQFRWT RDGVHFKPKE ELGVTVYQSP HSGSFTITGN NSNFAQRFQG IYRCFASNKL
     GTAMSHEIRL MAEGAPKWPK ETVKPVEVEE GESVVLPCNP PPSAEPLRIY WMNSKILHIK
     QDERVTMGQN GNLYFANVLT SDNHSDYICH AHFPGTRTII QKEPIDLRVK ATNSMIDRKP
     RLLFPTNSSS HLVALQGQPL VLECIAEGFP TPTIKWLRPS GPMPADRVTY QNHNKTLQLL
     KVGEEDDGEY RCLAENSLGS ARHAYYVTVE AAPYWLHKPQ SHLYGPGETA RLDCQVQGRP
     QPEVTWRING IPVEELAKDQ KYRIQRGALI LSNVQPSDTM VTQCEARNRH GLLLANAYIY
     VVQLPAKILT ADNQTYMAVQ GSTAYLLCKA FGAPVPSVQW LDEDGTTVLQ DERFFPYANG
     TLGIRDLQAN DTGRYFCLAA NDQNNVTIMA NLKVKDATQI TQGPRSTIEK KGSRVTFTCQ
     ASFDPSLQPS ITWRGDGRDL QELGDSDKYF IEDGRLVIHS LDYSDQGNYS CVASTELDVV
     ESRAQLLVVG SPGPVPRLVL SDLHLLTQSQ VRVSWSPAED HNAPIEKYDI EFEDKEMAPE
     KWYSLGKVPG NQTSTTLKLS PYVHYTFRVT AINKYGPGEP SPVSETVVTP EAAPEKNPVD
     VKGEGNETTN MVITWKPLRW MDWNAPQVQY RVQWRPQGTR GPWQEQIVSD PFLVVSNTST
     FVPYEIKVQA VNSQGKGPEP QVTIGYSGED YPQAIPELEG IEILNSSAVL VKWRPVDLAQ
     VKGHLRGYNV TYWREGSQRK HSKRHIHKDH VVVPANTTSV ILSGLRPYSS YHLEVQAFNG
     RGSGPASEFT FSTPEGVPGH PEALHLECQS NTSLLLRWQP PLSHNGVLTG YVLSYHPLDE
     GGKGQLSFNL RDPELRTHNL TDLSPHLRYR FQLQATTKEG PGEAIVREGG TMALSGISDF
     GNISATAGEN YSVVSWVPKE GQCNFRFHIL FKALGEEKGG ASLSPQYVSY NQSSYTQWDL
     QPDTDYEIHL FKERMFRHQM AVKTNGTGRV RLPPAGFATE GWFIGFVSAI ILLLLVLLIL
     CFIKRSKGGK YSVKDKEDTQ VDSEARPMKD ETFGEYRSLE SDNEEKAFGS SQPSLNGDIK
     PLGSDDSLAD YGGSVDVQFN EDGSFIGQYS GKKEKEAAGG NDSSGATSPI NPAVALE
//
